Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$3.90
+4.3%
$3.84
$2.60
$7.77
$212.32M1.62181,217 shs101,782 shs
Oculis Holding AG stock logo
OCS
Oculis
$19.65
+1.9%
$18.65
$10.79
$23.08
$841.81M0.3545,426 shs12,408 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$24.46
+2.4%
$21.85
$16.16
$26.55
$967.94M0.74207,288 shs182,782 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$4.64
+2.9%
$4.59
$2.03
$6.07
$705.29M0.712.00 million shs1.61 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
+4.28%+0.78%+2.36%-15.03%+15.38%
Oculis Holding AG stock logo
OCS
Oculis
+1.92%+2.13%+3.37%-0.15%+67.95%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+2.43%-1.01%+5.25%+13.71%+38.66%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
+2.88%+5.45%-3.93%-20.95%+119.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.3665 of 5 stars
1.01.00.00.00.62.50.6
Oculis Holding AG stock logo
OCS
Oculis
2.0629 of 5 stars
3.53.00.00.01.90.00.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.9803 of 5 stars
0.84.02.51.13.33.32.5
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.2159 of 5 stars
3.42.00.04.23.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.00
Hold$4.002.56% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.3379.81% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.67
Reduce$20.80-14.96% Downside
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
2.83
Moderate Buy$6.2534.70% Upside

Current Analyst Ratings Breakdown

Latest DSGN, PAHC, XERS, and OCS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
5/9/2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$6.00 ➝ $7.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$29.00 ➝ $32.00
4/17/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/15/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$20.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$4.28 per shareN/A
Oculis Holding AG stock logo
OCS
Oculis
$780K1,099.90N/AN/A$1.91 per share10.29
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B0.97$2.16 per share11.30$6.34 per share3.86
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$203.07M3.57N/AN/A($0.20) per share-23.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$49.59M-$0.99N/AN/AN/AN/A-22.85%-22.02%8/4/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/19/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7831.3611.650.452.68%30.51%6.89%8/27/2025 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$54.84M-$0.30N/AN/AN/A-20.25%N/A-12.07%8/6/2025 (Estimated)

Latest DSGN, PAHC, XERS, and OCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.28-$0.31-$0.03-$0.31N/AN/A
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/8/2025Q1 2025
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.07-$0.06+$0.01-$0.06$57.61 million$57.80 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.96%N/A61.54%N/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Latest DSGN, PAHC, XERS, and OCS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
28.37
28.37
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/A
1.72
1.17

Institutional Ownership

CompanyInstitutional Ownership
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
31.20%
Oculis Holding AG stock logo
OCS
Oculis
N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.56%
CompanyEmployeesShares OutstandingFree FloatOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4056.77 million39.06 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
290156.38 million149.25 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$3.90 +0.16 (+4.28%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$3.50 -0.40 (-10.26%)
As of 06/23/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Oculis stock logo

Oculis NASDAQ:OCS

$19.65 +0.37 (+1.92%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$19.64 0.00 (-0.03%)
As of 06/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$24.46 +0.58 (+2.43%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$24.46 -0.01 (-0.02%)
As of 06/23/2025 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma stock logo

Xeris Biopharma NASDAQ:XERS

$4.64 +0.13 (+2.88%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$4.60 -0.04 (-0.84%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.